Insulin Aspart (Fiasp®)
Indication
For the treatment of diabetes mellitus type 1 and 2 in adults
Green (Restricted)
Brand:
Fiasp®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
Must be commenced by a healthcare professional who is appropriately trained and experienced in the initiation of insulin.
Insulin Aspart (Fiasp®) is recommended for the treatment of diabetes mellitus in adults who are suitable for NovoRapid® and their diabetes cannot be adequately managed with alternative formulary choices and at least one of the following applies:
-
where the prescriber believes a faster onset of action would be beneficial to the patient
-
where a patient requires ‘tight’ control of blood sugar levels
-
where a patient has rapid post meal increase in blood sugar levels
Recommendation
LSCMMG Recommendation:
Green (Restricted)
Reason for decision:
Suitable for initiation in primary care in line with restrictions
Supporting documents: